Skip to content
Oncomedics logo — 1 patient - 1 tumour - 1 Oncogramme® - 1 treatment

Oncomedics

1 patient - 1 tumour - 1 Oncogramme® - 1 treatment

Founded 2006 11 employees Angel Biotechnology, Pharmaceutical

General Information

Company Name Oncomedics
Founded Year 2006
Employees 11
Industries Biotechnology, Pharmaceutical
Funding Stage Angel
Social

BounceWatch is an independent company data service, not affiliated with Oncomedics. To contact Oncomedics, visit oncomedics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Oncomedics compare?

A PDF of Oncomedics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Oncomedics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Oncomedics

Oncomedics is a biotechnology company, part of CliniSciences Group, focusing on personalizing cancer treatments. It develops in vitro diagnostic medical devices to assist surgeons, pathologists, and oncologists in identifying the most effective treatments for individual patients. The company's flagship product, Oncogramme®, evaluates the anti-cancer activity of existing drugs by testing them directly on a patient's operated tumor. This approach, similar to an antibiogram, assesses drug efficacy ex vivo, providing personalized chemotherapy options for patients with stage IV colorectal cancer since 2016. Oncomedics plans to optimize the Oncogramme® for other cancers like breast and ovarian cancer, further enhancing treatment accuracy. Established in 2006, Oncomedics received an Angel Round investment from Limousin Business Angels on 29 November 2017. The company operates in the Biotechnology and Pharmaceutical industries, showing potential for innovative and personalized cancer treatment solutions.

Business keywords: oncology, personalized medicine, cancer treatments, in vitro diagnostics, tumor testing, chemotherapy, precision medicine, drug efficacy, colorectal cancer, breast cancer, ovarian cancer, ex vivo testing, decision support

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Angel Round Undisclosed 1
Limousin Business Angels
29 Nov 2017

Oncomedics Alternatives & Competitors

View All Alternatives
Oncomedics vs

Innovative therapies harnessing the power of PARP inhibitors to combat advanced cancers

Series C
Biotechnology, Health Care
Oncomedics vs

Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.

Pre-Seed
1 employees
Biotechnology, Health and Wellness
Oncomedics vs
Aummune
Aummune Israel

WE ARE ALL UNIQUE SO IS AUMMUNE. The future of personalized therapy for cancer

18 employees
Biotechnology, Design

FAQ About Oncomedics

1 patient - 1 tumour - 1 Oncogramme® - 1 treatment
Oncomedics was founded in 2006.
Oncomedics operates in Biotechnology and Pharmaceutical. Its work centres on oncology, personalized medicine, cancer treatments and in vitro diagnostics.
Oncomedics has approximately 11 employees.
Oncomedics has completed 1 funding round. The latest funding stage is Angel.
Top alternatives and competitors to Oncomedics include BiPar Sciences, AlloMek Therapeutics LLC, Aummune, Theramir Ltd, ESPERANCE PHARMACEUTICALS, INC.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oncomedics and BiPar Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Oncomedics, https://www.bouncewatch.com/company/oncomedics, updated 2 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout